Shots:
- Daiichi Sankyo to conduct two-part P-I study assessing U3-1402+ Tagrisso as both a 1L and 2L dual regimen in patients with advanced or mNSCLC with an EGFR exon 19 deletion or L858R mutation
- The dose-escalation part will assess the safety & tolerability of different dosing combinations of dual regimen to determine the recommended dose while the second part of the study (dose expansion) will include a 1L and 2L cohort to further evaluate the anti-tumor activity and safety of the regimen
- In the 1L cohort, patients will receive dual regimens and patients in the 2L cohort will be randomized in a ratio (1:1) to receive treatment with U3-1402 as monothx. or in combination with Tagrisso. 258 patients will be enrolled in the study, which will be conducted in NA, EU, and Asia including Japan
Click here to read full press release/ article | Ref: Daiichi Sankyo | Image: StraitTimes
